NeuroOne Collaborates with Mayo Clinic on Pediatric Brain Cancer Research Using Drug Delivery Platform

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a collaboration with Mayo Clinic to support a newly funded research program evaluating a novel treatment approach for pediatric diffuse midline glioma (DMG), one of the most aggressive and difficult-to-treat childhood brain cancers. The program is supported by a grant from the Children's Cancer Research Fund (CCRF) awarded to Mayo Clinic investigators Dr. David Daniels and Dr. Liang Zhang.

The research project aims to address a fundamental challenge in treating malignant brain tumors: achieving and maintaining therapeutic drug concentrations within the tumor. While convection-enhanced delivery (CED) allows drugs to bypass the blood-brain barrier through direct intracranial infusion, therapeutic benefit may be limited by rapid drug clearance from the treatment site. The Mayo Clinic team will evaluate a novel combination therapy strategy designed to enhance intratumoral drug retention by modulating drug efflux mechanisms, with the goal of prolonging therapeutic exposure following localized drug delivery. The project will begin with large animal studies and may expand to human studies if successful.

The study will utilize NeuroOne's investigational drug delivery neural device technology, which combines precision intracranial drug delivery with simultaneous neural recording. This integrated approach enables targeted therapy while providing real-time physiologic monitoring throughout treatment, offering investigators insight into drug delivery and its effects on the surrounding neural environment.

The CCRF award marks an important milestone in advancing this therapeutic approach toward clinical evaluation. The collaboration expands NeuroOne's growing portfolio of drug delivery initiatives and reflects increasing interest from leading academic investigators and biopharmaceutical companies in the Company's drug delivery platform. For more information, visit nmtc1.com.

"This collaboration with Mayo Clinic represents another important milestone in the continued expansion of our drug delivery platform," said David Wambeke, Chief Business Officer of NeuroOne. "We believe our technology has the potential to become an enabling platform for targeted intracranial therapies by combining precision drug delivery with real-time neural recording. We are honored to support Mayo Clinic's efforts to develop new treatment options for children facing these devastating brain tumors."